A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience.

J Clin Med · 2023 · PMC10342289 · PMID 37445562

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The meta-analysis showed a trend toward an increased risk of MACE with baricitinib versus TNFis that was importantly driven by data from the SNDS administrative claims database; however, their analysis of data from the ARTIS registry did not show an increased risk.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.